{
    "clinical_study": {
        "@rank": "82436", 
        "arm_group": {
            "arm_group_label": "SL-701; Imiquimod Cream 5% and Leukine as adjuvants", 
            "arm_group_type": "Experimental", 
            "description": "SL-701 in Montanide 1.0mL injection taken from 0.7mL of SL-701 mixed at 1:1 ratio with 0.7mL of Montanide every 14 days for the first 155 days then every 28 days thereafter.\nImiquimod Cream 5% applied with each SL-701 administration and 24 hours after each SL-701 administration\nLeukine [Granulocyte macrophage-colony stimulating factor (GM-CSF)] 150 micrograms administered within 20 minutes after each SL-701 administration"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the safety and efficacy of SL-701 as a treatment\n      for recurrent glioblastoma multiform (GBM)."
        }, 
        "brief_title": "Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme", 
        "completion_date": {
            "#text": "April 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Adult Brain Glioblastoma", 
            "Glioblastoma Multiforme"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Glioblastoma", 
                "Glioma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18 years of age or older.\n\n          -  Histologically confirmed GBM or World Health Organization (WHO) Grade IV variants\n             (gliosarcoma, glioblastoma with oligodendroglial features, or giant cell\n             glioblastoma).\n\n          -  Unequivocal evidence of a first tumor recurrence or progression on the initial\n             treatment regimen (prior to enrollment on this study), consisting of surgical\n             resection, radiation, and temozolomide chemotherapy, as assessed by MRI or CT scan of\n             the brain with and without contrast within 14 days prior to the start of SL-701.  If\n             receiving corticosteroids, the dose must be stable or decreasing for at least 5 days\n             prior to the scan.  Patients unable to undergo MRI because of non-compatible devices\n             can be enrolled, provided CT scans are obtained and are of sufficient quality.\n             Patients without non-compatible devices may not have CT scans performed to meet this\n             requirement.  For each patient, the same imaging technique should be performed\n             throughout the study, for purposes of assessing tumor response or progressive disease\n             (PD).\n\n          -  For patients who have undergone resection of recurrent or progressive tumor prior to\n             study enrollment, the following conditions must apply:\n\n               -  Recovery from the effects of surgery.\n\n               -  Residual disease following resection of recurrent tumor is not mandated for\n                  eligibility into the study.  To best assess the extent of residual disease\n                  post-operatively, an MRI should be performed:\n\n                    -  No later than 96 hours (h) in the immediate post-operative period; or\n\n                    -  At least 4 weeks post-craniotomy (7 days for stereotactic biopsy), within\n                       14 days prior to the start of SL-701, and on a corticosteroid dosage that\n                       has been stable or decreasing for at least 5 days.\n\n          -  No evidence of hemorrhage on the baseline MRI or CT scan other than those that are\n             Grade \u2264 1 and either post-operative or stable on at least two consecutive scans.\n\n          -  Recovery from prior therapy toxicity, defined as resolution of all treatment-related\n             adverse events (AEs) to Grade \u2264 1 or pre-treatment baseline (except alopecia and\n             lymphopenia).\n\n          -  At least 12 weeks from prior radiotherapy to the start of SL-701 unless there is new\n             enhancement outside of the radiation field or unequivocal histopathologic evidence of\n             recurrent tumor.\n\n          -  No chemotherapy or investigational agent for at least 3 weeks prior to the start of\n             SL-701, with at least 6 weeks of elapsed time from last dose of nitrosoureas.\n\n          -  Human leukocyte antigen (HLA)-A2 positive.\n\n          -  If tumor tissue is collected and available prior to study entry, post-vaccine, or at\n             any time point throughout the duration of the study, then a sample must be submitted\n             for immunohistochemical analysis.\n\n          -  Karnofsky performance status (KPS) score \u2265 70%.\n\n          -  Adequate organ function, including the following:\n\n               -  Absolute neutrophil count (ANC) \u2265 1,000/\u03bcL, platelets \u2265 100,000/\u03bcL.\n\n               -  Serum creatinine < 1.5 \u00d7 the upper limit of normal (ULN).\n\n               -  Bilirubin < 1.5 \u00d7 ULN.\n\n               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 \u00d7 ULN.\n\n          -  Women of childbearing potential must have a negative serum or urine pregnancy test\n             within 3 days prior to the start of SL-701 treatment.\n\n          -  Female patients of childbearing potential and sexually active male patients must\n             agree to use an acceptable form of contraception for heterosexual activity (ie, oral\n             contraceptives, double barrier methods, hormonal injectable, transdermal, or\n             implanted contraceptives, tubal ligation, or vasectomy of their sexual partner(s) for\n             > 40 days before Screening, during the study, and for 60 days after the last dose of\n             study drug.  Men should not donate semen during the study and for 60 days after the\n             last dose of study drug.\n\n          -  Female patients without childbearing potential (spontaneous amenorrhea for > 12\n             months or surgically sterilized by tubal ligation, hysterectomy, or bilateral\n             oophorectomy > 6 months before Screening) are eligible for inclusion without\n             contraceptive use restriction.\n\n          -  Able and willing to comply with protocol requirements, in the opinion of the\n             investigator.\n\n          -  A written and voluntarily signed informed consent must be obtained from the patient\n             or legally authorized representative, in accordance with local regulations, before\n             the initiation of any study related procedures.  The patient or legally authorized\n             representative must be able to read and understand the informed consent form (ICF).\n\n        Exclusion Criteria:\n\n          -  Prior cancer chemotherapy, bevacizumab (or other vascular endothelial growth factor\n             [VEGF]/VEGF receptor [VEGFR]-directed agent), or an investigational agent for\n             recurrent/progressive GBM or prior bevacizumab as part of initial therapy.\n\n          -  Contrast-enhancing tumor that is any of the following:\n\n               -  Multi-focal (defined as two separate areas of contrast enhancement measuring at\n                  least 1 cm in 2 planes that are not contiguous on either fluid-attenuated\n                  inversion recovery (FLAIR) or T2 sequences);\n\n               -  Associated with either diffuse subependymal or leptomeningeal dissemination; or\n\n               -  \u2265 4 cm in any dimension.\n\n          -  Requirement of systemic corticosteroid therapy > 4 mg/day of dexamethasone or\n             equivalent or requirement of increasing dose of systemic corticosteroids during the 7\n             days prior to the start of SL-701 treatment.\n\n          -  Surgical resection or major surgical procedure within 4 weeks prior to the start of\n             SL-701, or stereotactic biopsy within 7 days prior to the start of SL-701.\n\n          -  Radiation therapy, local therapy (except for surgical re-resection), or systemic\n             therapy following first recurrence/progressive disease.  Excluded local therapies\n             include stereotactic radiation boost, implantation of carmustine biodegradable wafers\n             (Gliadel), intratumoral or convection-enhanced delivery administered agents, etc.\n\n          -  Active infection requiring intravenous antibiotics.\n\n          -  History of cancer (other than GBM) within the past 2 years that has metastatic or\n             local recurrence potential and could negatively impact survival and/or potentially\n             confound tumor response assessments within this study.\n\n          -  Clinically significant cardiovascular disease (eg, uncontrolled or any New York Heart\n             Association Class 3 or 4 congestive heart failure, uncontrolled angina, history of\n             myocardial infarction or stroke within 6 months of study entry, uncontrolled\n             hypertension or clinically significant arrhythmias not controlled by medication).\n\n          -  Known immunosuppressive disease or active systemic autoimmune disease such as\n             systemic lupus erythematosus, human immunodeficiency virus infection, Hepatitis B, or\n             Hepatitis C, or has taken an immunosuppressive agent within 4 weeks prior to the\n             start of SL-701 treatment.  Patients with vitiligo, type 1 diabetes mellitus,\n             hypothyroidism due to autoimmune condition only requiring hormone replacement\n             therapy, psoriasis not requiring systemic therapy, or conditions not expected to\n             recur in the absence of an external trigger are permitted to enroll.\n\n          -  Any condition which in the investigator's opinion makes the patient unsuitable for\n             study participation."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02078648", 
            "org_study_id": "STML-701-0114"
        }, 
        "intervention": [
            {
                "arm_group_label": "SL-701; Imiquimod Cream 5% and Leukine as adjuvants", 
                "intervention_name": "SL-701; Imiquimod Cream 5%; Leukine 150 micrograms", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "SL-701; Imiquimod Cream 5% and Leukine as adjuvants", 
                "intervention_name": "Imiquimod Cream 5%", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "SL-701; Imiquimod Cream 5% and Leukine as adjuvants", 
                "intervention_name": "Leukine 150 micrograms", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Imiquimod"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Glioma Associated Antigen", 
            "Vaccine", 
            "Adult", 
            "Recurrent Glioblastoma", 
            "Immunotherapy"
        ], 
        "lastchanged_date": "May 28, 2014", 
        "location": {
            "contact": {
                "email": "smarl1@hfhs.org", 
                "last_name": "Stephanie Marl, RN", 
                "phone": "313-916-7231"
            }, 
            "facility": {
                "address": {
                    "city": "Detroit", 
                    "country": "United States", 
                    "state": "Michigan", 
                    "zip": "48202"
                }, 
                "name": "Henry Ford Health System"
            }, 
            "investigator": {
                "last_name": "Tom Mikkelsen, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1/2 Study of SL-701, a Subcutaneously Injected Multivalent Glioma-Associated Antigen Vaccine, in Adult Patients With Recurrent Glioblastoma Multiforme (GBM)", 
        "overall_contact": {
            "email": "erowinsky@stemline.com", 
            "last_name": "Eric Rowinsky, MD", 
            "phone": "646-502-2304"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Characterize the safety and tolerability of SL-701", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 6 months and ongoing"
            }, 
            {
                "measure": "Estimate the percent of patients alive 12 months after the initiation of SL-701 (OS-12)", 
                "safety_issue": "No", 
                "time_frame": "up to 12 months"
            }, 
            {
                "measure": "Estimate the objective response rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02078648"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Estimate duration of response", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Estimate the percent of patients alive and progression-free survival at 6 months (PFS-6) after the initiation of SL-701.", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 months"
            }, 
            {
                "measure": "Estimate the distributions of progression-free survival (PFS) and overall survival (OS).", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }
        ], 
        "source": "Stemline Therapeutics, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Stemline Therapeutics, Inc.", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}